The Neuroblastoma drugs in development market research report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuroblastoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued products.

GlobalData tracks 175 drugs in development for Neuroblastoma by 143 companies/universities/institutes. The top development phase for Neuroblastoma is preclinical with 75 drugs in that stage. The Neuroblastoma pipeline has 144 drugs in development by companies and 31 by universities/ institutes. Some of the companies in the Neuroblastoma pipeline products market are: U.S. National Institutes of Health, F. Hoffmann-La Roche and Bristol-Myers Squibb.

The key targets in the Neuroblastoma pipeline products market include Cells Expressing Ganglioside GD2, ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC, and N Myc Proto Oncogene Protein (Class E Basic Helix Loop Helix Protein 37 or MYCN).

The key mechanisms of action in the Neuroblastoma pipeline product include Cytotoxic To Cells Expressing Ganglioside GD2 with 20 drugs in Phase II. The Neuroblastoma pipeline products include 15 routes of administration with the top ROA being Intravenous and 19 key molecule types in the Neuroblastoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.

Neuroblastoma overview

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes, and difficulty with movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, or urine test. It may be controlled by chemotherapy, radiation therapy, stem cell transplant, and medication such as monoclonal antibody regimens.

For a complete picture of Neuroblastoma’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.